Françoise M.
- Country
- France
- Department
- Nuclear Medecine
Research Overview
- Exploratory study evaluating the relevance of [68Ga]Ga-PentixaFor for initial staging and detection of minimal residual disease in multiple myeloma patients eligible for autologous stem cell transplantation less than 66 years included in the prospective IFM 2020-02.
- Evaluation of Baricitinib in Combination with Standard Care for Treatment of Large Inflammatory Hepatocellular Adenomas in Histologically Confirmed Patients
- Evaluation of [68Ga]Ga-PentixaFor PET for Initial Staging and Therapeutic Assessment in Symptomatic Multiple Myeloma Patients at Diagnosis or Relapse
Data & Insights
Has run more than one trial at 2 of 17 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in the study of multiple myeloma, with particular emphasis on innovative diagnostic approaches for disease staging and monitoring.
- Initial disease staging
- Minimal residual disease detection
- Bone marrow assessment
Advanced imaging techniques are employed to evaluate bone marrow lesions and extramedullary disease.
Hepatology
The investigator focuses on the treatment of inflammatory liver adenomas, exploring novel therapeutic approaches for both male and female patients.
- JAK1/2 inhibitor therapy
- Non-surgical treatment options
- Large adenoma management
Treatment strategies incorporate both pharmacological interventions and lifestyle modifications for optimal patient outcomes.
Diagnostic Imaging
The investigator evaluates advanced molecular imaging techniques for cancer diagnosis and treatment response assessment.
- PET imaging applications
- Disease progression monitoring
- Therapeutic response evaluation
Specialized focus on radiotracer-based imaging for hematologic malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.